Biden's Drug Price Negotiations: Medicare Savings to Hit $6 Billion in 2026

The U.S. government is set to save $6 billion in the first year from reduced prices on 10 top-selling prescription drugs for Medicare through Biden's Inflation Reduction Act. These savings, effective in 2026, also translate to $1.5 billion in reduced out-of-pocket costs for Medicare-covered Americans. Despite significant industry pushback, further drug price negotiations are slated for early next year.

The U.S. government will save $6 billion in the first year from lower prices the Biden administration negotiated on 10 top-selling prescription drugs for the Medicare health program, officials announced Thursday.

President Joe Biden's Inflation Reduction Act, signed into law in 2022, allows Medicare to negotiate prices for some costly drugs that cover 66 million people. These new prices, effective in 2026, will be unveiled later today. The administration stated that this would also save $1.5 billion in out-of-pocket costs for Medicare beneficiaries, which include popular diabetes treatments Januvia and Jardiance, along with blood thinners Eliquis and Xarelto and leukemia drug Imbruvica.

Despite the lack of detailed pricing information or reasons why the full $6 billion savings won't be passed on to patients, the administration aims to alleviate voters' concerns about high drug prices ahead of the Nov. 5 presidential election. Vice President Kamala Harris highlighted the law, passed with her tie-breaking Senate vote, as a crucial step towards affordable health care. Secretary Xavier Becerra described the negotiations as comprehensive and intense, while the pharmaceutical industry continues to resist, warning of potential cuts to drug development programs.